{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.2","upperLimit":"84.7","value":"69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG000","title":"Phase1b/Phase 2"}],"paramType":"NUMBER","populationDescription":"Phase 2 subjects include all subjects who participated in phase 1b. Subjects evaluated for sustained response includes participants who had achieved an NIH-defined CR or PR.","reportingStatus":"POSTED","timeFrame":"Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.","title":"Sustained Response Rate as the Percentage of Participants With Sustained Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}